NEW YORK, Sept. 10-Tranzyme has launched a research collaboration with BD Technologies, the two companies said today. Tranzyme also said today that it will also open a new lab for neurosensory disease research in BD Technologies' Research Triangle Park incubator.
For the research collaboration, Tranzyme will provide its gene transfer and protein expression technologies, which BD Technologies will use in specific cell lines for drug discovery, cell and tissue engineering.
BD has the right to market commercial products generated through this agreement, and will pay fees to Tranzyme for product sales. Tranzyme will have access to other BD Technologies intellectual property for its own drug development efforts in sensory system disease, as well as assistance in developing new collaborations with other divisions of BD.
Tranzyme expects that its new Research Triangle Park labs will allow the company to develop new collaborations with biotech companies in the area.
Tranzyme, which is based in Birmingham, Ala., focuses on genomics-based treatment for sensory diseases, neurodegenerative disease and viruses like HIV.